头孢呋新/他唑巴坦对临床常见革兰阳性菌的体外抗菌活性研究  

In vitro antibacterial activities of cefurixime/tazobactam against clinical isolates gram positive gucci.

作　　者：俞汝佳[1] 吕晓菊[1] 高燕渝[1] 马晓波[1] 杜蓉[1] 

机构地区：[1]四川大学华西医院感染性疾病中心抗感染药物研究室,四川省感染性疾病分子生物学重点实验室,四川成都610041

出　　处：《四川医学》2009年第2期179-181,共3页Sichuan Medical Journal

摘　　要：目的比较不同配比头孢呋新/他唑巴坦(cefuroxime/tazobactam1∶1、2∶1、4∶1)、头孢哌酮/舒巴坦、哌拉西林/他唑巴坦对临床分离的常见革兰阳性菌的体外抗菌活性,为新药的研发提供实验依据。方法以平皿二倍稀释法测定MIC值,以Nitrocefin纸片法测定产酶株。结果对本次研究收集的2005年1月～2006年1月共计致病菌104株进行了MIC测定,其中85%的菌株产β-内酰胺酶,不同配比的头孢呋新/他唑巴坦联合制剂对除MRS以外的其它革兰阳性球菌有很好的抗菌作用,头孢呋新/他唑巴坦3个配比中以1∶1配比的抗菌作用较为合理。结论头孢呋新/他唑巴坦(1∶1)为一个强效广谱杀菌药物。Objective To study the in vitro activity of cefuroxime/tazobactam combined at various ratios（ 1 ： 1.2： 1,4： 1 ） ,cefoperazone/shubatan,piperacillin/tazobactam against clinical isolates, in order to provide the evidence for the new drug research of drug manufactory. Methods MIC were determined by the two fold agar dilution,β-lactamase by nitrocefin sllp. Results MIC of cefuroxime/ tazobactam against 97 clinical isolates（with % β-lactamase）were measured, which were isolated between January 2005 and January 2006. The vitro activity against gram positive gueci was significantly enhanced by various ratios combined use of eefuroxime/tazobactam , except methicillin resistant staphylococcus（ MRS）. the enzyme inhibitor of tazobaetam has significantly enhanced the antibacterial activities of cefuroxime, the MIC90 of cefuroxime/tazobactam （ 1 ： 1 ） were dereased to 〉 256μg/ml. - 32μg/ml, 〉 256μg/ml - 64μg/ml, 〉 2.56μg/ml- 128μg/ml, 〉 256μg/ml- 128μg/ml, the resistance rate were obviously decreased. The vitro activity against gram positive coccus were significantly enhanced by various ratios combined use of eefuroxime/tazobaetam, except to methicillin resistant staphylococcus aures （ MRSA ） . The best antibacterial activity of cefuroxime/tazobaetam was achieved in the ratio of （ 1 ： 1 ） . Conclusion the combination of cefuroxime/tazobactam（ 1 ： 1 ）is an significant bactericidal medicine.

关 键 词：头孢呋新 他唑巴坦 体外抗菌活性 

分 类 号：R96[医药卫生—药理学]